Investment bank RBC Capital Markets has started covering 10x Genomics, and its initial take paints a company moving in two very different directions. On one side, 10x dominates the fast-growing field of spatial biology. On the other, its older single-cell business looks set to tread water for years.
The contrast matters because it frames where 10x's future growth will come from — and what investors should watch closely.
The hot side: spatial profiling
RBC says 10x leads what it calls "high-plex" spatial molecular profiling, a technology that lets researchers see where genes and proteins are active inside intact tissue samples. The "high-plex" part refers to the ability to measure many targets at once — hundreds or even thousands of molecules in a single experiment.
According to RBC, 10x holds more than 60% of that market. The category is still early in its adoption curve, and RBC expects it to grow at a double-digit rate. That growth is expected to continue even before the launch of Atera, an upcoming product that could expand the company's reach further.
For context, spatial biology is a relatively new area of life-science research. Traditional methods often break tissue apart to analyze its contents, losing the spatial context of where molecules sit. Spatial profiling keeps that layout intact, which can help researchers understand how diseases like cancer develop and how cells interact in their natural environment.
The cold side: single-cell sequencing
The less encouraging part of RBC's assessment concerns 10x's single-cell business. This technology lets scientists analyze the genetic material of individual cells, rather than averaging across a whole tissue sample. It was a major growth driver for 10x in earlier years.
But RBC expects that segment to stay "mostly flat" over the next five years. That suggests the market may be maturing, with competition intensifying and many labs already equipped with the necessary instruments.
The contrast sets up a clear narrative: 10x's growth now hinges on how quickly spatial biology can scale, and whether Atera can accelerate that trend.
What it means for investors
For everyday investors, the key takeaway is that 10x Genomics is not a single-story stock. Its fortunes are tied to two very different product lines with very different trajectories.
If spatial biology continues to grow at double-digit rates and 10x maintains its dominant share, that could offset a stagnant single-cell business. But if spatial growth slows, or if competitors chip away at 10x's lead, the overall picture could weaken.
RBC's initiation is just one analyst's view, but it highlights the importance of segment-level performance. Investors should look for updates on spatial product sales, any details on Atera's launch timing, and how management addresses the single-cell slowdown in future earnings calls.
It's also worth remembering that life-science tool companies like 10x can be volatile. Their revenue depends on research budgets at universities, biotech firms, and pharmaceutical companies, which can fluctuate with funding cycles and economic conditions.
For now, the market seems to be weighing the same two-sided story. The stock's direction may depend on which side investors believe will dominate in the coming years.
As with any stock, it's wise to do your own research and consider how a company's growth drivers align with your own investment goals and risk tolerance.
